The Influence of Simvastatin on NGAL, Matrix Metalloproteinases and Their Tissue Inhibitors in Human Intraluminal

A Piechota-Polanczyk1, S Demyanets2, M Mittlboeck3

  • 1Department of Surgery, Division of Vascular Surgery, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.

Abstract

Insights

Simvastatin may alter matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) levels in abdominal aortic aneurysms (AAAs). Further research is needed to clarify statin therapy

Area of Science:

  • Cardiovascular Biology
  • Biochemistry
  • Pharmacology

Background:

  • Matrix metalloproteinases (MMPs) are crucial in abdominal aortic aneurysm (AAA) development.
  • The balance between MMPs, tissue inhibitors of MMPs (TIMPs), and neutrophil gelatinase-associated lipocalin (NGAL) influences protease activity.
  • Understanding these interactions is key to managing AAA progression.

Purpose of the Study:

  • To investigate the impact of simvastatin on MMPs, TIMPs, and NGAL in AAA tissues.
  • To compare gene expression and protein levels between patients on simvastatin and those not on statins.

Main Methods:

  • Analysis of MMP2, MMP9, TIMP1, TIMP2, and NGAL gene expression via real-time PCR.
  • Quantification of MMP2, MMP9, MMP9/TIMP1, MMP9/TIMP2, and MMP9/NGAL protein levels using ELISA.
  • Patients were matched for age, sex, and AAA diameter.

Main Results:

  • MMP2 and MMP9 levels (mRNA and protein) were similar between groups.
  • A significant decrease in TIMP1 mRNA was observed in AAA tissue from patients on simvastatin.
  • An increased concentration of the MMP9/TIMP2 complex was found in intraluminal thrombi (ILTs) of patients on simvastatin.

Conclusions:

  • Simvastatin may modulate protease and inhibitor concentrations within AAA walls and ILTs.
  • Further studies are warranted to elucidate the specific effects of statin therapy on the MMP/TIMP system in AAAs.
  • These findings highlight potential therapeutic targets for AAA management.